Raynauds Disease - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Raynauds Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H2 2016', provides an overview of the Raynauds Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
- The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects
- The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Raynauds Disease

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Raynauds Disease Overview 6
Therapeutics Development 7
Pipeline Products for Raynauds Disease - Overview 7
Raynauds Disease - Therapeutics under Development by Companies 8
Raynauds Disease - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Raynauds Disease - Products under Development by Companies 12
Raynauds Disease - Companies Involved in Therapeutics Development 13
Allergan Plc 13
Apricus Biosciences, Inc. 14
Covis Pharmaceuticals, Inc. 15
Human Stem Cells Institute 16
Raynauds Disease - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
acetylcysteine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
alprostadil - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ELS-140 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Neovasculgen - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
nitroglycerin - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
onabotulinumtoxin A - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Raynauds Disease - Dormant Projects 43
Raynauds Disease - Discontinued Products 44
Raynauds Disease - Product Development Milestones 45
Featured News & Press Releases 45
Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference 45
Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros 45
Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference 45
Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May 45
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa 46
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon 46
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 47
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 48
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon 48
Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana 48
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon 49
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa 49
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma 50
Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Number of Products under Development for Raynauds Disease, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Raynauds Disease - Pipeline by Allergan Plc, H2 2016 13
Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2016 14
Raynauds Disease - Pipeline by Covis Pharmaceuticals, Inc., H2 2016 15
Raynauds Disease - Pipeline by Human Stem Cells Institute, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Raynauds Disease - Dormant Projects, H2 2016 43
Raynauds Disease - Discontinued Products, H2 2016 44